Laser zaps stubborn heart blockages in new study
NCT ID NCT07206082
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a special laser can help open heart arteries that are too hard or blocked for standard balloon treatment. About 230 adults with severe coronary artery disease will receive the laser procedure and be followed for one year. The goal is to see if the laser safely improves blood flow without major complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 230 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2020
- Expected to finish
-
Oct 2025
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with indication for PCI and undilatable or uncrossable lesions treated with ELCA
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged over 18 years. * Patients with either stable coronary artery disease or acute coronary syndromes as the clinical presentation. * Patients with severe coronary lesions (\>70% by visual estimation) in native vessels or coronary bypass grafts. * "Uncrossable" coronary lesions (i.e., lesions that cannot be crossed with a 0.7:1 balloon after successful guidewire passage) or "Undilatable" lesions (i.e., those in which balloon dilation with a 1:1 non-compliant balloon at 18 atm results in less than 80% expansion relative to the distal reference vessel diameter; this group includes both de novo lesions and in-stent restenosis or underexpanded stents). Exclusion Criteria: * Patients with known allergies to aspirin (ASA), clopidogrel, prasugrel, or ticagrelor. * Patients unable to provide informed consent, either personally or through a legal representative. * Patients with clinical or hemodynamic instability defined as: sustained hypotension (systolic blood pressure ≤ 90 mmHg for ≥ 30 minutes or use of pharmacological and/or mechanical support to maintain an SBP ≥90 mmHg) or evidence of end-organ hypoperfusion including urine output of \<30 mL/h, cool extremities, altered mental status, and/or serum lactate \>2.0 mmol/L. * Patients with significant comorbidities and a life expectancy of less than one year.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Calcified coronary artery disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Universitario La Paz
Madrid, Madrid, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can heart stent patients go home in 6 hours?
- Can AI read heart scans to predict the next heart attack?
- Can a new drug cool the hidden inflammation that fuels heart disease?
- New CT scanner aims to cut unnecessary heart procedures
- Heart bypass surgeons test which vein layout keeps grafts open
- A soft patch that watches your heart beat in real time